Multidisciplinary Surgical Approach to Increase Survival for Advanced Ovarian Cancer in a Tertiary Gynaecological Oncology Centre.
Journal
Annals of surgical oncology
ISSN: 1534-4681
Titre abrégé: Ann Surg Oncol
Pays: United States
ID NLM: 9420840
Informations de publication
Date de publication:
Jan 2024
Jan 2024
Historique:
received:
16
06
2023
accepted:
26
09
2023
medline:
7
12
2023
pubmed:
25
10
2023
entrez:
24
10
2023
Statut:
ppublish
Résumé
The purpose of this paper is to report on changes in overall survival, progression-free survival, and complete cytoreduction rates in the 5-year period after the implementation of a multidisciplinary surgical team (MDT). Two cohorts were used. Cohort A was a retrospectively collated cohort from 2006 to 2015. Cohort B was a prospectively collated cohort of patients from January 2017 to September 2021. This study included 146 patients in cohort A (2006-2015) and 174 patients in cohort B (2017-2021) with FIGO stage III/IV ovarian cancer. Median follow-up in cohort A was 60 months and 48 months in cohort B. The rate of primary cytoreductive surgery increased from 38% (55/146) in cohort A to 46.5% (81/174) in cohort B. Complete macroscopic resection increased from 58.9% (86/146) in cohort A to 78.7% (137/174) in cohort B (p < 0.001). At 3 years, 75% (109/144) patients had disease progression in cohort A compared with 48.8% (85/174) in cohort B (log-rank, p < 0.001). Also at 3 years, 64.5% (93/144) of patients had died in cohort A compared with 24% (42/174) of cohort B (log-rank, p < 0.001). Cox multivariate analysis demonstrated that MDT input, residual disease, and age were independent predictors of overall (hazard ratio [HR] 0.29, 95% confidence interval [CI] 0.203-0.437, p < 0.001) and progression-free survival (HR 0.31, 95% CI 0.21-0.43, p < 0.001). Major morbidity remained stable throughout both study periods (2006-2021). Our data demonstrate that the implementation of multidisciplinary-team, intraoperative approach allowed for a change in surgical philosophy and has resulted in a significant improvement in overall survival, progression-free survival, and complete resection rates.
Identifiants
pubmed: 37875740
doi: 10.1245/s10434-023-14423-1
pii: 10.1245/s10434-023-14423-1
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
460-472Informations de copyright
© 2023. Society of Surgical Oncology.
Références
Stewart CRC, Lockwood S. Ovarian cancer: an integrated review. Semin Oncol Nurs. 2019;35(2):151–6.
doi: 10.1016/j.soncn.2019.02.001
pubmed: 30867104
Lheureux SGC, Vergote I, Oza AM. Epithelial ovarian cancer. Lancet. 2019;393(10177):1240–53.
doi: 10.1016/S0140-6736(18)32552-2
pubmed: 30910306
Adamopoulou K, Gkamprana AM, Patsouras K, Halkia E. Addressing hepatic metastases in ovarian cancer: recent advances in treatment algorithms and the need for a multidisciplinary approach. World J Hepatol. 2021;13(9):1122–31.
doi: 10.4254/wjh.v13.i9.1122
pubmed: 34630879
pmcid: 8473491
Taylor C, Munro AJ, Glynne-Jones R, Griffith C, Trevatt P, Richards M, et al. Multidisciplinary team working in cancer: what is the evidence? BMJ. 2010;340:c951.
doi: 10.1136/bmj.c951
pubmed: 20332315
Pillay B, Wootten AC, Crowe H, Corcoran N, Tran B, Bowden P, et al. The impact of multidisciplinary team meetings on patient assessment, management and outcomes in oncology settings: a systematic review of the literature. Cancer Treat Rev. 2016;42:56–72.
doi: 10.1016/j.ctrv.2015.11.007
pubmed: 26643552
Falzone L, Scandurra G, Lombardo V, Gattuso G, Lavoro A, Distefano AB, et al. A multidisciplinary approach remains the best strategy to improve and strengthen the management of ovarian cancer (review). Int J Onco. 2021;59(1):53.
doi: 10.3892/ijo.2021.5233
Mangone L, Marinelli F, Bisceglia I, Braghiroli MB, Mastrofilippo V, Cerullo L, et al. Ovarian cancer in a Northern Italian Province and the multidisciplinary team. Cancers (Basel). 2022;15(1):299.
doi: 10.3390/cancers15010299
pubmed: 36612295
Rausei S, Uccella S, D’Alessandro V, Gisone B, Frattini F, Lianos G, et al. Aggressive surgery for advanced ovarian cancer performed by a multidisciplinary team: a retrospective analysis on a large series of patients. Surg Open Sci. 2019;1(1):43–7.
doi: 10.1016/j.sopen.2019.05.005
pubmed: 32754692
pmcid: 7391894
Abdallah R, Atallah D, Bitar N, Chahine G, Ghanem H, Ghosn M, et al. Consensus on the management of platinum-sensitive high-grade serous epithelial ovarian cancer in Lebanon. Gynecol Oncol Rep. 2023;47:101186.
doi: 10.1016/j.gore.2023.101186
pubmed: 37181681
pmcid: 10173395
Woo YL, Kyrgiou M, Bryant A, Everett T, Dickinson HO. Centralisation of services for gynaecological cancers: a Cochrane systematic review. Gynecol Oncol. 2012;126(2):286–90.
doi: 10.1016/j.ygyno.2012.04.012
pubmed: 22507534
Vanderpuye VD, Clemenceau JRV, Temin S, Aziz Z, Burke WM, Cevallos NL, et al. Assessment of adult women with ovarian masses and treatment of epithelial ovarian cancer: ASCO resource-stratified guideline. JCO Glob Oncol. 2021;7:1032–66.
doi: 10.1200/GO.21.00085
pubmed: 34185571
Fotopoulou C, Hall M, Cruickshank D, Gabra H, Ganesan R, Hughes C, et al. British Gynaecological Cancer Society (BGCS) epithelial ovarian/fallopian tube/primary peritoneal cancer guidelines: recommendations for practice. Eur J Obstet Gynecol Reprod Biol. 2017;213:123–39.
doi: 10.1016/j.ejogrb.2017.04.016
pubmed: 28457647
Fotopoulou C, Planchamp F, Aytulu T, Chiva L, Cina A, Ergönül Ö, et al. European Society of Gynaecological Oncology guidelines for the peri-operative management of advanced ovarian cancer patients undergoing debulking surgery. Int J Gynecol Cancer. 2021;31(9):1199–206.
doi: 10.1136/ijgc-2021-002951
pubmed: 34407962
Colombo N, Sessa C, du Bois A, Ledermann J, McCluggage WG, McNeish I, et al. ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease†. Ann Oncol. 2019;30(5):672–705.
doi: 10.1093/annonc/mdz062
pubmed: 31046081
Mulligan KM, Glennon K, Donohoe F, O’Brien Y, Mc Donnell BC, Bartels HC, et al. Multidisciplinary surgical approach to increase complete cytoreduction rates for advanced ovarian cancer in a tertiary gynecologic oncology Center. Ann Surg Oncol. 2021;28(8):4553–60. https://doi.org/10.1245/s10434-020-09494-3 .
doi: 10.1245/s10434-020-09494-3
pubmed: 33423175
Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol. 2002;20(5):1248–59.
doi: 10.1200/JCO.2002.20.5.1248
pubmed: 11870167
Bryant A, Hiu S, Kunonga PT, Gajjar K, Craig D, Vale L, et al. Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery. Cochrane Database Syst Rev. 2022;9(9):CD015048. https://doi.org/10.1002/14651858 .
doi: 10.1002/14651858
pubmed: 36161421
Wallace S, Kumar A, Mc Gree M, Weaver A, Mariani A, Langstraat C, et al. Efforts at maximal cytoreduction improve survival in ovarian cancer patients, even when complete gross resection is not feasible. Gynecol Oncol. 2017;145(1):21–6.
doi: 10.1016/j.ygyno.2017.01.029
pubmed: 28159407
Gadducci A, Cosio S, Zizioli V, Notaro S, Tana R, Panattoni A, et al. Patterns of recurrence and clinical outcome of patients with stage IIIC to stage IV epithelial ovarian cancer in complete response after primary debulking surgery plus chemotherapy or neoadjuvant chemotherapy followed by interval debulking surgery: an Italian multicenter retrospective study. Int J Gynecol Cancer. 2017;27(1):28–36.
doi: 10.1097/IGC.0000000000000843
pubmed: 27870700
Harter P, Sehouli J, Vergote I, Ferron G, Reuss A, Meier W, et al. Randomized trial of cytoreductive surgery for relapsed ovarian cancer. N Engl J Med. 2021;385(23):2123–31.
doi: 10.1056/NEJMoa2103294
pubmed: 34874631
Shi T, Zhu J, Feng Y, Tu D, Zhang Y, Zhang P, et al. Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2021;22(4):439–49.
doi: 10.1016/S1470-2045(21)00006-1
pubmed: 33705695
Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011;365(26):2484–96.
doi: 10.1056/NEJMoa1103799
pubmed: 22204725
Aghajanian C, Blank SV, Goff BA, Judson PL, Teneriello MG, Husain A, et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol. 2012;30(17):2039–45.
doi: 10.1200/JCO.2012.42.0505
pubmed: 22529265
pmcid: 3646321
Tewari KS, Burger RA, Enserro D, Norquist BM, Swisher EM, Brady MF, et al. Final overall survival of a randomized trial of bevacizumab for primary treatment of ovarian cancer. J Clin Oncol. 2019;37(26):2317–28.
doi: 10.1200/JCO.19.01009
pubmed: 31216226
pmcid: 6879307
DiSilvestro P, Banerjee S, Colombo N, Scambia G, Kim B-G, Oaknin A, et al. Overall survival with maintenance olaparib at a 7-year follow-up in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: the SOLO1/GOG 3004 trial. J Clin Oncol. 2023;41(3):609–17.
doi: 10.1200/JCO.22.01549
pubmed: 36082969
Bartels HCRA, McSharry V, McVey R, Walsh T, O’Brien D, et al. A meta-analysis of morbidity and mortality in primary cytoreductive surgery compared to neoadjuvant chemotherapy in advanced ovarian malignancy. Gynecol Oncol. 2019;154(3):622–30.
doi: 10.1016/j.ygyno.2019.07.011
pubmed: 31349996
Cascales Campos AP, Gil AG, Gil Gómez E, González Sánchez R, Martínez García J, Alonso Romero JL, et al. Cytoreductive surgery with or without HIPEC after neoadjuvant chemotherapy in ovarian cancer: a phase 3 clinical trial. Ann Surg Oncol. 2022;29:2628–9. https://doi.org/10.1245/s10434-021-11177-6 .
doi: 10.1245/s10434-021-11177-6
Cianci S, Riemma G, Ronsini C, De Franciscis P, Torella M, Schiattarella A, et al. Hyperthermic intraperitoneal chemotherapy (HIPEC) for ovarian cancer recurrence: systematic review and meta-analysis. Gland Surg. 2020;9(4):1140–8.
doi: 10.21037/gs-20-335
pubmed: 32953629
pmcid: 7475376
Hung H-C, Hsu P-J, Chang T-C, Chou H-H, Huang K-G, Lai C-H, et al. The impact of multidisciplinary team approach on cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis. J Personal Med. 2021;11(12):1313.
doi: 10.3390/jpm11121313
Reuss ADBA, Harter P, Fotopoulou C, Sehouli J, Aletti G, et al. TRUST: trial of radical upfront surgical therapy in advanced ovarian cancer (ENGOT ov33/AGO-OVAR OP7). Int J Gynecol Cancer. 2019;29(8):1327–31.
doi: 10.1136/ijgc-2019-000682
pubmed: 31420412
Clavien PA, Barkun J, de Oliveira ML, Vauthey JN, Dindo D, Schulick RD, et al. The Clavien–Dindo classification of surgical complications: five-year experience. Ann Surg. 2009;250(2):187–96.
doi: 10.1097/SLA.0b013e3181b13ca2
pubmed: 19638912
Koole S, van Stein R, Sikorska K, Barton D, Perrin L, Brennan D, et al. Primary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC) for FIGO stage III epithelial ovarian cancer: OVHIPEC-2, a phase III randomized clinical trial. Int J Gynecol Cancer. 2020;30(6):888–92.
doi: 10.1136/ijgc-2020-001231
pubmed: 32205449
pmcid: 8202725
Koole SN, van Driel WJ, Sonke GS. Hyperthermic intraperitoneal chemotherapy for ovarian cancer: the heat is on. Cancer. 2019;125(Suppl 24):4587–93.
doi: 10.1002/cncr.32505
pubmed: 31967678
Glennon K, Mulligan K, Carpenter K, Mooney R, Mulsow J, McCormack O, et al. The addition of sodium thiosulphate to hyperthermic intraperitoneal chemotherapy with cisplatin in ovarian cancer. Gynecol Oncol Rep. 2021;37:100796.
doi: 10.1016/j.gore.2021.100796
pubmed: 34141848
pmcid: 8185237
Lyons YA, Reyes HD, McDonald ME, Newtson A, Devor E, Bender DP, et al. Interval debulking surgery is not worth the wait: a National Cancer Database study comparing primary cytoreductive surgery versus neoadjuvant chemotherapy. Int J Gynecol Cancer. 2020;154:210–1.
Ren Y, Jiang R, Yin S, You C, Liu D, Cheng X, et al. Radical surgery versus standard surgery for primary cytoreduction of bulky stage IIIC and IV ovarian cancer: an observational study. BMC Cancer. 2015;15(1):583.
doi: 10.1186/s12885-015-1525-1
pubmed: 26268818
pmcid: 4535562
Rauh-Hain JA, Melamed A, Wright A, Gockley A, Clemmer JT, Schorge JO, et al. Overall survival following neoadjuvant chemotherapy vs. primary cytoreductive surgery in women with epithelial ovarian cancer: analysis of the National Cancer Database. JAMA Oncol. 2017;3(1):76–82.
doi: 10.1001/jamaoncol.2016.4411
pubmed: 27892998
pmcid: 5548189
Chi DS, Eisenhauer EL, Zivanovic O, Sonoda Y, Abu-Rustum NR, Levine DA, et al. Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm. Gynecol Oncol. 2009;114(1):26–31.
doi: 10.1016/j.ygyno.2009.03.018
pubmed: 19395008
Vergote I, Tropé CG, Amant F, Kristensen GB, Ehlen T, Johnson N, et al. Neoadjuvant Chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010;363(10):943–53.
doi: 10.1056/NEJMoa0908806
pubmed: 20818904
Kehoe S, Hook J, Nankivell M, Jayson GC, Kitchener H, Lopes T, et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. Lancet. 2015;386(9990):249–57.
doi: 10.1016/S0140-6736(14)62223-6
pubmed: 26002111
Vergote I, Coens C, Nankivell M, Kristensen GB, Parmar MKB, Ehlen T, et al. Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials. Lancet Oncol. 2018;19(12):1680–7.
doi: 10.1016/S1470-2045(18)30566-7
pubmed: 30413383
Hiu S, Bryant A, Gajjar K, Kunonga PT, Naik R. Ultra-radical (extensive) surgery versus standard surgery for the primary cytoreduction of advanced epithelial ovarian cancer. Cochrane Database Syst Rev. 2022;30;8(8):CD007697. https://doi.org/10.1002/14651858 .
doi: 10.1002/14651858
pubmed: 36041232
Mangone L, Marinelli F, Bisceglia I, Braghiroli MB, Mastrofilippo V, Cerullo L, et al. Ovarian cancer in a Northern Italian Province and the multidisciplinary team. Cancers. 2023;15(1):299.
doi: 10.3390/cancers15010299
Elattar A, Bryant A, Winter-Roach BA, Hatem M, Naik R. Optimal primary surgical treatment for advanced epithelial ovarian cancer. Cochrane Database Syst Rev. 2011;2011(8):Cd007565.
pubmed: 21833960
pmcid: 6457688